Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

This phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SJG-136, a sequence-specific DNA cross-linking agent, in patients with advanced cancer. In schedule A, seven patients received escalating doses of SJG-136 (6, 12, 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2011-06, Vol.17 (11), p.3794-3802
Hauptverfasser:	PUZANOV, Igor, LEE, Wooin, ROTHENBERG, Mace L, CHEN, Alice P, WADE CALCUTT, M, HACHEY, David L, VERMEULEN, Wendy L, SPANSWICK, Victoria J, LIAO, Chih-Yi, HARTLEY, John A, BERLIN, Jordan D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Benzodiazepinones - adverse effects Benzodiazepinones - metabolism Benzodiazepinones - pharmacokinetics Benzodiazepinones - pharmacology Biological and medical sciences Dexamethasone - administration & dosage Dyspnea - chemically induced Edema - chemically induced Fatigue - chemically induced Female Humans Male Maximum Tolerated Dose Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasms - drug therapy Pharmacology. Drug treatments Pyrroles - adverse effects Pyrroles - metabolism Pyrroles - pharmacokinetics Pyrroles - pharmacology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!